You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The Rehovot, Israel-based precision medicine firm will use the funding to scale clinical trials and expansion to the UK.
The firm is focused on developing oncology drugs that target mutations in the RAS pathway.
The Swedish company is developing sequencing- and PCR-based tests and services that quantify aberrations in DNA, RNA, and circulating tumor DNA.
This new VC round brings the cancer informatics and precision medicine company's total fundraising to $520 million and its valuation to $3.1 billion.
